

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 August 2004 (12.08.2004)

PCT

(10) International Publication Number
WO 2004/066967 A3

(51) International Patent Classification⁷: A61K 31/56,
31/58, 31/585, 9/14, A61L 15/16, A61F 13/00

(21) International Application Number:
PCT/US2004/000941

(22) International Filing Date: 15 January 2004 (15.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/348,570 21 January 2003 (21.01.2003) US

(71) Applicants (for all designated States except US):
DIMERA INC. [US/US]; 2525 NW Lovejoy, Suite 311,
Portland, OR 97210 (US). HERMSMEYER, R., Kent
[US/US]; 2420 NE 61st Avenue, Portland, OR 97213 (US).

(74) Agent: EISENBERG, Howard; 2206 Applewood Court,
Perkasie, PA 18944 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
3 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND KIT FOR REDUCING THE SYMPTOMS OF PERIPHERAL VASCULAR DISEASE


(57) Abstract: A method for reducing the symptoms of peripheral vascular disease wherein a chemical agent that reduces peripheral vascular hyperreactivity in response to a stimulus for contraction of peripheral vascular musculature is administered to a subject in need thereof. Kits for administering the chemical agent to reduce the symptoms of peripheral vascular disease.

WO 2004/066967 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/00941

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 31/56, 31/58, 31/585, 9/14; A61L 15/16; A61F 13/00 US CL : 514/169, 170, 177, 178, 179, 180, 181, 182; 424/ 444, 447,449, 484 According to International Patent Classification (IPC) or to both national classification and IPC</p>																				
<p>B. FIELDS SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/169, 170, 177, 178, 179, 180, 181, 182; 424/ 444, 447,449, 484</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p> <p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet</p>																				
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category *</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>Y</td> <td>Database CAPLUS, AN 1943:5455, WALKER, T.C., Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease. Journal of Clinical Endocrinology. 1942, Vol. 2, pages 560-568. Abstract.</td> <td>1-39</td> </tr> <tr> <td>Y</td> <td>MYERS et al. Estrogen increase male rat aortic endothelial cell (RAEC) PGI2 release, Prostaglandins, leukotrienes and essential fatty acids. 1996, Vol. 54, No. 6, pages 403-409, see entire document.</td> <td>1-39</td> </tr> <tr> <td>Y</td> <td>US 5,612,051 A (YUE) 18 March 1997(18.03.1997), See the abstract, col. 7, line 14 to col. 8, lines 5, col. 9, line 64 to col. 10, line 20, col. 10, lines 59-64, and the claims.</td> <td>1-39</td> </tr> <tr> <td>Y</td> <td>EP 0 399 432 A2 (TAKEDA CHEMICAL INDUSTRIES) 28 November 1990, the abstract, page 3, lines, 31-34.</td> <td>1-39</td> </tr> <tr> <td>Y</td> <td>US 2002/0156090 A1 (DAY et al.) 24 October 2002(24.10.2002), the abstract, pages 2-3, and the claims.</td> <td>1-39</td> </tr> </tbody> </table>			Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	Y	Database CAPLUS, AN 1943:5455, WALKER, T.C., Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease. Journal of Clinical Endocrinology. 1942, Vol. 2, pages 560-568. Abstract.	1-39	Y	MYERS et al. Estrogen increase male rat aortic endothelial cell (RAEC) PGI2 release, Prostaglandins, leukotrienes and essential fatty acids. 1996, Vol. 54, No. 6, pages 403-409, see entire document.	1-39	Y	US 5,612,051 A (YUE) 18 March 1997(18.03.1997), See the abstract, col. 7, line 14 to col. 8, lines 5, col. 9, line 64 to col. 10, line 20, col. 10, lines 59-64, and the claims.	1-39	Y	EP 0 399 432 A2 (TAKEDA CHEMICAL INDUSTRIES) 28 November 1990, the abstract, page 3, lines, 31-34.	1-39	Y	US 2002/0156090 A1 (DAY et al.) 24 October 2002(24.10.2002), the abstract, pages 2-3, and the claims.	1-39
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
Y	Database CAPLUS, AN 1943:5455, WALKER, T.C., Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease. Journal of Clinical Endocrinology. 1942, Vol. 2, pages 560-568. Abstract.	1-39																		
Y	MYERS et al. Estrogen increase male rat aortic endothelial cell (RAEC) PGI2 release, Prostaglandins, leukotrienes and essential fatty acids. 1996, Vol. 54, No. 6, pages 403-409, see entire document.	1-39																		
Y	US 5,612,051 A (YUE) 18 March 1997(18.03.1997), See the abstract, col. 7, line 14 to col. 8, lines 5, col. 9, line 64 to col. 10, line 20, col. 10, lines 59-64, and the claims.	1-39																		
Y	EP 0 399 432 A2 (TAKEDA CHEMICAL INDUSTRIES) 28 November 1990, the abstract, page 3, lines, 31-34.	1-39																		
Y	US 2002/0156090 A1 (DAY et al.) 24 October 2002(24.10.2002), the abstract, pages 2-3, and the claims.	1-39																		
<p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.</p>																				
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed									
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family																			
"P" document published prior to the international filing date but later than the priority date claimed																				
<p>Date of the actual completion of the international search 30 October 2004 (30.10.2004)</p>		<p>Date of mailing of the international search report 20 DEC 2004</p>																		
<p>Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230</p>		<p>Authorized officer  Shengjun Wang Telephone No. (571) 272-1600</p>																		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/00941

Continuation of B. FIELDS SEARCHED Item 3:

CAS ONLINE, MEDLINE, BIOSIS search terms: peripheral vascular disease, Raynaud, hormone, androgen, extrogen, progesteron, testosterone, progestin, diabetes, gel, oral, cream, ointment, transdermal.